Compare Amphastar Pharmaceuticals Inc (AMPH) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Best Buy Co Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Best Buy Co Inc trades at $81.49 (market cap $17.45B). The key difference: Best Buy Co Inc is far larger — about 21.1× Amphastar Pharmaceuticals Inc's market cap, and Best Buy Co Inc pays a 4.64% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BBY | |
|---|---|---|
Market Cap | $826.08M | $17.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $84.00 |
52-Week Low | $16.87 | $55.52 |
Enterprise Value | $1.22B | $19.83B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Best Buy (BBY) trades at $82.80, up 3.51% with a bullish technical signal. The stock shows strong profitability with a 39.1% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic shifts under new CEO Jason Bonfig toward higher-margin services like retail media and marketplace expansion, alongside new product launches such as RGB LED TVs and Meta VR partnerships.
Outlook remains cautiously optimistic with a consensus price target of $82.18. The attractive 4.6% dividend yield and improving cash flow support income investors, but risks include macroeconomic pressures on consumer electronics spending and leadership transitions. Revenue declines since 2022 require monitoring for stabilization under new growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
